Published in Hospital Business Week, September 16th, 2007
This trend article about Maastricht University, Netherlands, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Researchers detail in "Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study," new data in acne vulgaris. "R115866 (Rambazole; Barrier Therapeutics NV, Geel, Belgium), a new-generation retinoic acid metabolism-blocking agent, is a nonretinoid compound enhancing intracellularly the endogenous levels of all-trans-retinoic acid by blocking its catabolism. By virtue of this property,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.